Medication Reaction
Conditions
Keywords
cancer, chemotherapy, EGFR inhibitors, tretinoin, EGFRi drug rash
Brief summary
This research is being done to study whether using of topical tretinoin can help prevent the common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I) medications such ascetuximab or erlotinib. Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and topical or oral antibiotics. However, there has not yet been a study looking at a way to prevent this common side effect from occurring, and topical tretinoin may be useful in reducing the rash. Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing rashes associated with EGFR-I's.
Interventions
DRUGTretinoin
tretinoin 0.025% cream
Sponsors
Johns Hopkins University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or over * Scheduled to begin treatment with an EGFR inhibitor drug
Exclusion criteria
* Pregnant or nursing * History of bleeding disorder * History of keloids or large, thick, puffy-looking scars in the last 10 years * Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin, tazarotene/Tazorac)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EGFRi rash severity | 8 weeks |
Outcome results
None listed